[go: up one dir, main page]

MX2020010085A - Formulaciones que contienen péptidos. - Google Patents

Formulaciones que contienen péptidos.

Info

Publication number
MX2020010085A
MX2020010085A MX2020010085A MX2020010085A MX2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A
Authority
MX
Mexico
Prior art keywords
formulation
peptide
containing formulations
salt
glutamic acid
Prior art date
Application number
MX2020010085A
Other languages
English (en)
Inventor
Kenneth Cundy
Kent K Grindstaff
Remi Magnan
Original Assignee
Cohbar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohbar Inc filed Critical Cohbar Inc
Publication of MX2020010085A publication Critical patent/MX2020010085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona una formulación que comprende ácido glutámico, o una sal de este, y una cantidad eficaz de un péptido. La invención también proporciona un método para preparar la formulación, métodos para tratar una afección usando la formulación y un kit que contiene componentes de la formulación. La invención proporciona además una formulación de liberación sostenida para fármacos que comprenden ácido glutámico, o una sal de este, y una cantidad de un péptido.
MX2020010085A 2018-03-27 2019-03-27 Formulaciones que contienen péptidos. MX2020010085A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648746P 2018-03-27 2018-03-27
PCT/US2019/024331 WO2019191264A1 (en) 2018-03-27 2019-03-27 Peptide-containing formulations

Publications (1)

Publication Number Publication Date
MX2020010085A true MX2020010085A (es) 2021-01-15

Family

ID=66103053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010085A MX2020010085A (es) 2018-03-27 2019-03-27 Formulaciones que contienen péptidos.

Country Status (11)

Country Link
US (1) US11517608B2 (es)
EP (1) EP3773627A1 (es)
JP (1) JP2021519321A (es)
KR (1) KR20200139723A (es)
CN (1) CN112040958A (es)
AU (1) AU2019243724A1 (es)
CA (1) CA3097341A1 (es)
IL (1) IL277466A (es)
MX (1) MX2020010085A (es)
TW (1) TW202002996A (es)
WO (1) WO2019191264A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
CN118236470A (zh) * 2024-03-29 2024-06-25 无锡市第二人民医院 MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
CN119241659B (zh) * 2024-10-08 2025-09-19 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2008153788A2 (en) 2007-05-30 2008-12-18 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
JP2011517548A (ja) 2007-06-29 2011-06-16 セントコア・オーソ・バイオテツク・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法及び使用
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
US8637470B2 (en) 2008-05-01 2014-01-28 The Regents Of The University Of California Small humanin-like peptides
WO2012009709A1 (en) 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
AU2017336440B2 (en) * 2016-09-28 2022-06-02 Cohbar, Inc. Therapeutic MOTS-c related peptides

Also Published As

Publication number Publication date
CN112040958A (zh) 2020-12-04
JP2021519321A (ja) 2021-08-10
KR20200139723A (ko) 2020-12-14
WO2019191264A1 (en) 2019-10-03
US11517608B2 (en) 2022-12-06
IL277466A (en) 2020-11-30
AU2019243724A1 (en) 2020-10-29
US20210030835A1 (en) 2021-02-04
EP3773627A1 (en) 2021-02-17
TW202002996A (zh) 2020-01-16
CA3097341A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2020003190A (es) Degradadores de proteinas y usos de los mismos.
MX2020010085A (es) Formulaciones que contienen péptidos.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX386413B (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
AU2017242867A8 (en) Vortioxetine pamoic acid salt and crystal form thereof
EA202091372A1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
TW201625535A (en) Inhibitors of histone demethylases
ZA202108987B (en) 1-amino-1-cyclopropanecarboxylic acid hudrochloride formulations
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
PH12018000077B1 (en) A pharmaceutical composition for neuropathic pain
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
SG11201901317TA (en) Anti-pd-l1 antibody
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
ZA202102816B (en) High concentration protein formulation
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
MX2021006102A (es) Suministro mejorado de agentes grandes.
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
SG11201901617PA (en) Azole compound ophthalmic preparation